Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Medical Condition: Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]"
journalStr:"WHO International Clinical Trials Registry Platform"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=10
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=10
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=10
PubPharm (152)
91
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab to Evaluate Daratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab to Evaluate Daratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
92
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administrationin Combination with Carfilzomib and Dexamethasone (DKd) Compared withCarfilzomib and Dexamethasone (Kd) in Participants with Multiple Myelomawho have been Previously Treated with Daratumumab to EvaluateDaratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administrationin Combination with Carfilzomib and Dexamethasone (DKd) Compared withCarfilzomib and Dexamethasone (Kd) in Participants with Multiple Myelomawho have been Previously Treated with Daratumumab to EvaluateDaratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
93
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab to Evaluate Daratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab to Evaluate Daratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
94
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial : Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial - HOVON 126 MM
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
95
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab to Evaluate Daratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab to Evaluate Daratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
96
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administrationin Combination with Carfilzomib and Dexamethasone (DKd) Compared withCarfilzomib and Dexamethasone (Kd) in Participants with Multiple Myelomawho have been Previously Treated with Daratumumab to EvaluateDaratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administrationin Combination with Carfilzomib and Dexamethasone (DKd) Compared withCarfilzomib and Dexamethasone (Kd) in Participants with Multiple Myelomawho have been Previously Treated with Daratumumab to EvaluateDaratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
97
A Clinical Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab to Evaluate Daratumumab Retreatment : A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab to Evaluate Daratumumab Retreatment
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
98
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial : Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial - HOVON 126 MM
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
99
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab : Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab - -
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
100
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab : Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab - -
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
[1]
« Vorheriger
5
6
7
8
9
10
11
12
13
14
15
Nächster »
[16]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Thema: Medical Condition: Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Medienart
152
Aufsätze
152
E-Artikel
152
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
152
610
Medical Condition: Multiple Myeloma MedDRA vers...
152
Recruitment Status: Authorised-recruitment may ...
152
Study Type: Interventional
92
Phase: Phase 3
56
Phase: Phase 2
2
Phase: Phase 1
2
Phase: Phase 4
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
14
2023
54
2022
46
2021
38
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
152
Englisch
Haven't found what you're looking for?
Wird geladen...